News

Seattle, WA
Presage Biosciences, a biotechnology company whose mission is understanding the complexity of drug response in the tumor microenvironment, today announced completion of a first-of-its-kind Phase 0 clinical study utilizing its CIVO® (Comparative In Vivo Oncology) multiplexed microdosing...
Seattle, WA
Read on:
By using a device that allows researchers to see how tiny amounts of cancer drugs perform while inside the body, Takeda has shown that two of its investigational therapies could potentially help break down the barriers that protect solid tumors from being targeted by the human immune system.
Seattle, WA
Read on:
Presage announced the closing of a $13 million financing and commencement of new research collaborations with Merck, known as MSD outside of the United States and Canada, and Maverick Therapeutics. The financing includes $7 million raised from new investors, including…
Seattle, WA
Presage Biosciences announced a new research collaboration with Takeda Pharmaceutical Company Limited (Takeda) that will utilize CIVO to evaluate multiple investigational oncology agents and combinations in Phase 0 trials…
Seattle, WA
Presage Biosciences announced today that the U.S. Food and Drug Administration (FDA) has approved its first Exploratory Investigational New Drug (IND) application for a Phase 0 study utilizing its CIVO platform.…
Seattle, WA
Presage Biosciences, a cancer biotechnology company pioneering a new cancer drug development approach using its CIVO™ multiplexed intratumoral microdosing platform, today announced it has entered into a research collaboration…
Seattle, WA
Research agreement to support Phase 0 tumor microdosing studies…
Seattle, WA
Presage Biosciences, a cancer biotechnology company pioneering the use of intratumoral microdosing for Phase 0 investigation of early development candidates, today announced that it has closed a Series D financing...…
Seattle, WA
Presage Biosciences, a cancer biotechnology company pioneering the use of intratumoral microdosing, today announced that it entered into a research alliance with Codiak BioSciences.…
Seattle, WA
The grant is aimed at advancing Presage’s next generation of intratumoral microdosing platform to assess immuno-oncology drug combinations.…
San Diego and Seattle
MEI Pharma, Inc (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it has entered into a license agreement with Presage Biosciences, Inc. for voruciclib…
June 3, 2016 • Seattle, WA
Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drugs and combinations directly in patient tumors, announced today the appointment of David Johnson to its board of…
Seattle, WA
Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drug combinations directly in patient tumors, will present preclinical data showing that the company’s clinical-stage…
Seattle, WA
Presage Biosciences, an oncology company that has established a novel drug development approach to assess drug combinations directly in-patient tumors, announced today that is has entered into a multi-year extension of its …
Seattle, WA
Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the formation of a Medical…
Seattle, WA
Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that it has in-licensed …
Seattle, WA
Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Tachi…
Seattle, WA
Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, today announced that it has secured a …
Seattle, WA
A newly developed technology for simultaneously comparing response to multiple cancer drugs or combinations while a tumor is still in a patient’s body has been shown to accurately predict systemic response to the drugs, …
Seattle, WA
Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that the U.S. Patent and Trade…
Seattle, WA
Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Brad Margus…
Seattle, WA
Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human data much earlier in drug development and clinical trials, announced today that it has expanded its cancer research …
Seattle, WA
Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human efficacy data much earlier in drug development and clinical trials, announced today that the U.S. Patent and Trademark…
Seattle, WA
Presage Biosciences, a biotechnology company focused on bringing the earliest human efficacy data possible into cancer drug development, presented preclinical data showing that microinjection of several standard-of-care …
Seattle, WA
Presage Biosciences, a leader in precision oncology, has been named by FierceBiotech as one of 2013’s Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is…
Seattle, WA
Presage Biosciences, a leader in precision oncology, today announced the initiation of a clinical trial and the first patient use of CIVO™, the company’s precision oncology platform designed to improve treatment decisions for…
Seattle, WA
Presage Biosciences, a leader in discovering effective cancer drug combinations, today announced that it has entered into a strategic collaboration agreement with Celgene Corporation under which Presage and Celgene will take …
Seattle, WA
Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company. The research agreem…
Seattle, WA
Presage Biosciences, a privately held biotechnology company that works with oncology-focused pharmaceutical companies through strategic alliances using its patented three-dimensional in vivo drug analysis platform, announced …